Finn Sawyer Access to Cancer Testing Act
HB1620, the Finn Sawyer Access to Cancer Testing Act, would require Medicare, Medicaid, and CHIP to cover certain cancer diagnostic and laboratory tests beginning in 2027. The bill defines these tests to include microarray analysis, DNA sequencing, RNA sequencing, whole-exome sequencing, other next-generation sequencing, and the explanation and interpretation of those results when furnished to a person diagnosed with cancer. It also limits how often the same genetic content can be covered, generally allowing coverage at diagnosis, at recurrence, and as needed for treatment planning or monitoring.
In addition to the coverage mandate, the bill directs the Secretary of Health and Human Services, working with the National Human Genome Research Institute, to run an education and awareness program for physicians and the public on genomic testing, its uses, and the role of genetic counselors. The program would also encourage graduate medical education and continuing medical education on molecular diagnostics in cancer care, especially at diagnosis and recurrence.
The bill would amend the Social Security Act to add these cancer tests as covered benefits under Medicare and as required medical assistance under Medicaid, including benchmark coverage rules, while also specifying payment rules and an exception to the Medicare deductible for these services. For Medicaid, the bill includes a delayed effective date and a state-legislation accommodation if a state needs to enact conforming laws. It also extends coverage requirements to CHIP, including pregnancy-related assistance where applicable.
The overall sentiment in the available record appears supportive and noncontroversial, but the bill has only been introduced and referred to committee, with no recorded votes or committee debate provided. The bipartisan list of original cosponsors suggests broad interest in expanding access to cancer testing and genomic medicine. Because no transcript or vote history is available, there is no documented opposition in the provided materials.
The main policy issue is access to advanced cancer diagnostics versus the cost and utilization implications of mandating coverage across major public insurance programs. The bill addresses potential overuse by limiting coverage of repeated tests that report the same genetic content, but it still raises implementation questions for federal and state programs, especially Medicaid and CHIP administration. Any contention would likely center on coverage scope, reimbursement levels, and whether states and plans can absorb the added costs and operational requirements.
The bill would amend the Social Security Act to create a new covered category for cancer diagnostic and laboratory tests under Medicare, require Medicaid coverage of those tests as medical assistance, and require CHIP coverage beginning January 1, 2027. It would also modify Medicare payment and deductible rules, add a frequency limitation for repeat testing, and provide a state-legislation transition rule for Medicaid plans that need conforming state action. Separately, it would direct HHS to launch a genomic testing education and awareness program and encourage medical education on molecular diagnostics.
The available context suggests generally favorable sentiment. The bill’s title, subject matter, and bipartisan introduction indicate support for expanding access to cancer testing and genomic diagnostics. There are no recorded votes or committee transcripts in the provided materials, so there is no evidence of organized opposition or amendment debate in the record supplied. The absence of recorded controversy suggests the bill was at an early stage and framed as a patient-access and cancer-care improvement measure.
No specific contention is documented in the provided record, but the likely areas of debate are the cost of mandating coverage in Medicare, Medicaid, and CHIP, the administrative burden on states and managed care plans, and the scope of tests included under the definition of cancer diagnostic and laboratory tests. The bill’s limitation on repeated testing indicates an effort to address concerns about overutilization, while supporters would likely emphasize earlier diagnosis, better treatment planning, and improved access to precision oncology. Any opposition would most likely come from budget-minded lawmakers, state administrators, or payers concerned about reimbursement and implementation.